Silk Road Medical price target lowered to $45 from $50 at Stifel

Stifel analyst Rick Wise lowered the firm’s price target on Silk Road Medical to $45 from $50 and keeps a Buy rating on the shares. Stifel is “pleased and relieved” by the company’s outperformance in Q2, the analyst says. With its salesforce, growing product portfolio, and geographic expansion ahead, Stifel believes the company has “many years of above-average growth ahead.”